Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy

31 August 2025 (10:45 - 10:55)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Martha Grogan

Mayo Clinic, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail

Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101

Doctor F. Aus Dem Siepen (Heidelberg, DE)

Abstract Slides Video

Presentation thumbnail

Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy

Doctor B. Forst (Phoenix, US)

Abstract Slides Video

Presentation thumbnail

HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Doctor P. Garcia-Pavia (Majadahonda, ES)

Abstract Slides Video

Presentation thumbnail

RNA interference therapy in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Mr G. Arrighini (Bologna, IT)

Abstract Slides Video

Presentation thumbnail

The UNOS experience on heart transplantation for amyloid cardiomyopathy

Associate Professor A. Briasoulis (Athens, GR)

Abstract Slides Video

Access the full session

Session thumbnail

Therapeutic advances in amyloid cardiomyopathy

The Event

Event poster

ESC Congress 2025

31 August 2025 10:45 CET

You may be interested in

Congress Session

Advances in amyloidosis

Congress Session

Therapeutic advances in amyloid cardiomyopathy

Congress Presentation

Turning data into decisions: insights from trials and real-world experience in ATTR-CM

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources